Urinary Bladder Neoplasms clinical trials
The registry lists 1,614 studies for Urinary Bladder Neoplasms across more than 10 countries. 421 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 640
- Recruiting
- 324
- Status unknown
- 199
- Active, not recruiting
- 154
- Terminated
- 142
- Not yet recruiting
- 84
Phase
- Phase 2
- 514
- Phase 1
- 295
- Phase 3
- 167
- Phase 4
- 30
- Early Phase 1
- 23
Where
- United States
- 734
- China
- 192
- France
- 138
- Italy
- 133
- Canada
- 133
- United Kingdom
- 120
Who runs them
National Cancer Institute (NCI) (65) · Memorial Sloan Kettering Cancer Center (37) · Mansoura University (29) · M.D. Anderson Cancer Center (28) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (19) · Assiut University (19) · AstraZeneca (17) · Tianjin Medical University Second Hospital (14)
Studies
Recruiting first, then most recently updated. Showing 50 of 1,614 — search for more.
- A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in KoreaNot yet recruitingNCT07735793
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 216 countries
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsRecruitingNCT07277413Phase 11 country
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingNCT07419295Phase 317 countries
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 11 country
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 22 countries
- Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder CancerNot yet recruitingNCT07800507Phase 1/21 country
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialRecruitingNCT07061964Phase 21 country
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingNCT06770582Phase 22 countries
- A Study of Surgical Techniques During CystectomyRecruitingNCT06703476Phase 31 country
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingNCT06814496Phase 1/21 country
- En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope DeviceRecruitingNCT042357641 country
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractRecruitingNCT07218380Phase 319 countries
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Not yet recruitingNCT07829783Phase 3
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseRecruitingNCT06529822Phase 11 country
- Prospective Bladder Cancer Infrastructure (ProBCI)RecruitingNCT045035771 country
- Prehabilitation in High-risk Oncologic SurgeryRecruitingNCT07638410Not applicable1 country
- A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder CancerRecruitingNCT07804056Phase 31 country
- Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingNCT06227065Phase 21 country
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingNCT05267626Phase 1/22 countries
- A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerNot yet recruitingNCT07827612Phase 21 country
- A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder CancerRecruitingNCT06733363Phase 21 country
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 21 country
- Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder CancerRecruitingNCT06394570Phase 1/21 country
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingNCT07667335Phase 1/21 country
- Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic AnalysisRecruitingNCT05464576Not applicable1 country
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasRecruitingNCT07217171Phase 11 country
- SL-28 for Advanced Solid TumoursRecruitingNCT07341737Phase 1/21 country
- Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)RecruitingNCT078205661 country
- Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingNCT07643519Phase 2
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruitingNCT050594445 countries
- Feasibility of HISA During TURBT for NMIBCNot yet recruitingNCT07817173Not applicable1 country
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)RecruitingNCT06833073Phase 219 countries
- TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian FederationRecruitingNCT070389281 country
- An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGAvailableNCT064439441 country
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 32 countries
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)RecruitingNCT07222488Phase 1/212 countries
- A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving TrialRecruitingNCT06040762Not applicable1 country
- Acupuncture and Exercise for EV-Pembro-Induced Peripheral NeuropathyRecruitingNCT07548476Not applicable1 country
- Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyNot yet recruitingNCT07189793Phase 21 country
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruitingNCT000018231 country
- Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTNot yet recruitingNCT07808216Phase 2
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerRecruitingNCT07206225Phase 16 countries
- First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsRecruitingNCT06644755Phase 15 countries
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 18 countries
- Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled TrialRecruitingNCT07463963Not applicable1 country
- Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyRecruitingNCT071443195 countries
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 16 countries
- Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCRecruitingNCT06567743Phase 22 countries